spacer
home > ict > summer 2018 > pro translation
PUBLICATIONS
International Clinical Trials

PRO Translation

The use of patient-reported outcomes (PROs) has grown considerably in the last several decades, spreading into new technologies and supporting the evaluation of endpoints in clinical trials and regulatory decision-making. With this growth in their use and impact comes an increased obligation to ensure PROs collect high-quality data, both in terms of properly defining the constructs that PROs intend to measure and ensuring that patients are able to comprehend their content despite typically low familiarity with PROs and the language they use compared to healthcare professionals. An analysis was conducted on the term ‘disease activity’ as used in four separate PROs. Through investigation of patients’ comprehension of this term and their reactions to its translation in a variety of languages and countries, suggestions can be drawn to improve the quality of data collected by PROs that assess disease activity.

Study Objective

The objective of the study was to identify terminology found in PROs that causes difficulty in translation and comprehension. Identifying such terminology and solutions that improve translation and patient comprehension is critical to increasing the validity of PROs and their treatment insights. As such, the use of the term ‘disease activity’ was investigated in PROs across 29 languages. Disease activity can be defined as “manifestations of a disease” and typically appears in instruments assessing the state of a patient’s disease signs and symptoms (1-2).

Previous translation projects have suggested that disease activity is frequently identified by patients as a problematic term. However, to date, a systematic analysis of instruments that use this term has not been conducted. Here, data is presented from several translation projects involving the term ‘disease activity’, illustrating the difficulties that patients face in interpreting the term, and ways to mitigate these difficulties through revised or expanded translations are proposed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Tim Poepsel is a Survey Research Analyst with RWS Life Sciences. He has a BA in linguistics from Northwestern University, US, and a PhD in psychology and language science from Penn State University, US. Tim specialises in the area of linguistic validation, and his research focusses on the patient perspective in the development and administration of clinical outcome assessment (COA) instruments.

Barbaa Brandrt is Survey Research Analyst Team Lead at RWS Life Sciences. Barbara has 17 years of experience in COAs, linguistic validation, translatability assessment, and electronic COAs and usability testing. She has a BA in linguistics and psychology and an MA in Survey Research from the University of Connecticut, US.

Elizabeth Yohe Moore is the COA process development lead at RWS Life Sciences with eight years of healthcare industry experience. She received a BA in neuroscience and economics from Oberlin College, US, and an MPH from Northwestern University, US.

Elizabeth McCullough is the Manager of Linguistic Validation Services at RWS Life Sciences. Elizabeth has worked in the areas of medical translation and linguistic validation for 10 years. She holds an MA in translation from the Institute for Applied Linguistics at Kent State University, US.

Shawn McKown is the Senior Director and Practice Lead of Linguistic Validation at RWS Life Sciences. Shawn has worked with COAs, patient-reported outcomes, and linguistic validation within the clinical trial space for over 15 years and holds an MA from the University of Chicago, US.
spacer
Dr Tim Poepsel
spacer
spacer
spacer
Barbara Brandt
spacer
spacer
spacer
Elizabeth Yohe Moore
spacer
spacer
spacer
Elizabeth McCullough
spacer
spacer
spacer
Shawn McKown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance

Phlexglobal Ltd

Looking at some of the challenges of traditional paper-based Trial Master Files (TMFs), and how they can be overcome with Phlexglobal's best in breed electronic TMF system, PhlexEview.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement